

Supplementary Information for

Economic evaluation of disease elimination: an extension to the net benefits framework and

application to human African trypanosomiasis

Marina Antillon, Ching-I Huang, Kat S. Rock, Fabrizio Tediosi

Corresponding Author Marina Antillon.

E-mail: marina.antillon@swisstph.ch

This PDF file includes:

- Supplementary text
- Figs. S1 to S5

- Tables S1 to S16
- SI References

¹³ **Supporting Information Text**

¹⁴ **1. Overview of the net-benefits framework**

¹⁵ As mentioned in the keystone measure of value-for-money in cost-effectiveness analysis is the incremental cost-effectiveness ¹⁶ ratio (ICER), defined as the ratio of the difference in costs and the difference in health effects of two interventions:

$$
17
$$
Incremental cost-effectiveness ratio (ICER) = $\frac{\Delta \text{Costs}}{\Delta \text{Eftects}} = \frac{\Delta C}{\Delta E}$,

¹⁸ where effects are usually denominated in disability-adjusted life-years (DALYs) (as in the current analysis) or in quality-adjusted

¹⁹ life-years (QALYs). Here, costs are denominated in US\$, even if a particular resource was provided in-kind (i.e. unpaid work ²⁰ by community health workers) or borrowed capital (i.e. a microscope that could have been used for a campaign of another ²¹ disease).

 The ratio is easily generalized to select among multiple interventions by taking the incremental costs and benefits of each intervention compared to the next-best strategy, where a strategy is defined as a combination of interventions and the set of strategies proposed in the analysis are mutually exclusive. In most of the literature, health effects are denominated in DALYs (usually for low- and middle-income countries) and in QALYs (usually for high-income countries). Both measures incorporate a

factor of disease severity so as to make the measures comparable across diseases under study.

The net benefits framework was developed to account extend concepts in cost-effectiveness while incorporating parameter uncertainty $(1, 2)$ $(1, 2)$ $(1, 2)$. This framework makes use of two metrics: the net health benefits (NHB) and the net monetary benefits (NMB) – the latter is the the metric on which we will focus in the current paper (although a formulation with the net health benefits is also possible). The NMB is characterized as a simple arithmetic rearrangement of the ICER:

$$
ICER = \frac{\Delta C}{\Delta E} \le \lambda^{\text{WTP}} \n0 \le (\lambda^{\text{WTP}} \times \Delta E) - \Delta C \n= \text{Net Monetary Benefits (NMB)}
$$

In order to assess the impact of parameter uncertainty on costs and effects, and by extension, on the choice of strategy, one of the most common procedures is a Monte Carlo procedure drawing random samples from the given parameters, and applying it to the health and cost model. One can determine a strategy's probability to be cost-effective for at a specific "willingness-to-pay" (WTP) threshold:

$$
Pr(CE_{Strategy\ j} | \lambda^{WTP}) = \frac{1}{N} \sum_{i=1}^{N} M(\theta_i),
$$

where

$$
M(\theta_i) = \begin{cases} 1 & \text{argmax}_{k \in 1:J} \text{NMB}(k, \theta_i | \lambda^{WTP}) = j\\ 0 & \text{Otherwise} \end{cases}
$$

27 and where θ_i represents the *i*th iterate from the parameter space, in a simulation with *N* Monte Carlo iterations, and NMB=0

 f_{28} for $j=1$ (the comparator). Therefore, the probability that strategy *j* is cost-effective at λ^{WTP} is the proportion of times in a

²⁹ Monte Carlo simulation of *N* iterates where the strategy *j* has the highest net benefits among all strategies at a given WTP.

The normative interpretation can be made in two ways: a risk-averse decision-maker will select the strategy that has the highest chance of being cost-effective; however, the risk-neutral decision-maker might not, due to an interesting feature in probabilistic simulations. One might note that in situations in which the probability distributions of the parameters in the simulation are asymmetric, some interventions might have a lower median than a mean, due to long tails in their distributions, thus sometimes yielding low probabilities of cost-effectiveness among all simulations but high expectations in the NMB. A risk-neutral decision-maker who looks only to maximize the health returns on a given WTP would choose the strategy with the highest expected NMB:

$$
\operatorname*{argmax}_{k \in 1:J} \mathbb{E}(\text{NMB}(k, \theta_i | \lambda^{\text{WTP}}))
$$

³⁰ That debate is beyond the scope of the paper, and we will proceed with an assumption of a risk-neutral decision-maker.

³¹ **2. Extension of net-benefits framework**

Following the manner of the net benefits framework, we propose a rearrangement and combination of elimination objectives, defined here as $ICER_{EOT}$ (where EOT is elimination of transmission), and objectives to avert disease burden, defined here as ICER_{DALY}:

$$
\text{ICER}_{\text{DALY}} = \frac{\Delta C_{\text{DALY}}}{\Delta \text{DALYs}} < \lambda_{\text{DALY}}^{\text{WTP}} \Rightarrow \text{NMB}_{\text{DALY}} = (\lambda_{\text{DALY}}^{\text{WTP}} \times \Delta \text{DALYs}) - \Delta C_{\text{DALY}}
$$

$$
\text{ICER}_{\text{EOT}} = \frac{\Delta C_{\text{EOT}}}{\Delta \mathbb{I}_{\text{EOT}}} < \lambda_{\text{EOT}}^{\text{WTP}} \times 100 \Rightarrow \text{NMB}_{\text{EOT}} = (\lambda_{\text{EOT}}^{\text{WTP}} \times \Delta \mathbb{I}_{\text{EOT}}) - \Delta C_{\text{EOT}}
$$

where

 $\Delta \mathbb{I}_{\text{EOT}} = \left\{ \begin{array}{l} -1 \\ 0 \\ 1 \end{array} \right.$ \int -1 The comparator strategy leads to elimination, but the candidate strategy does not 0 Neither or both interventions lead to elimination

1 Only one intervention leads to elimination

Then, we define the net monetary and elimination benefit, $NMEB(\theta_i)$, for each *i* of *N* iterations of the model as the sum of $\text{NMB}_{\text{PALY}}(\theta_i)$ and $\text{NMB}_{\text{EOT}}(\theta_i)$. C_{DALY} and C_{EOT} are rarely separable – especially in the presence of non-linearities of costs and transmission – so we simply continue to refer to total costs.

Net Monetary and Elimination Benefits $=NMEB(\theta_i)$

$$
= \text{NMB}_{\text{DALY}} + \text{NMB}_{\text{EOT}} \n\text{NMEB}(J, \theta_i | \text{WTP}_{\text{DALY}}, \lambda_{\text{EOT}}^{\text{WTP}}) = (\lambda_{\text{DALY}}^{\text{WTP}} \times \Delta \text{DALYs}(\theta_i)) + (\lambda_{\text{EOT}}^{\text{WTP}} \times \Delta \mathbb{I}_{\text{EOT}}(\theta_i)) - \Delta \text{C}(\theta_i) : \n\{j \in 2, ..., J\} \& \{i \in 1, ..., N\}
$$

³² Although one cannot purchase a service to make elimination certain, by taking into account the probability of elimination in

³³ each intervention, one can estimate the degree to which interventions are justified by traditional control concerns (money-

 $_{34}$ per-DALY-averted), namely the product of $\lambda_{\rm DALY}^{\rm WTP}$ and DALYs averted, and then consider the complement as the degree that ³⁵ strategies are defined by elimination concerns:

$$
\Delta C
$$
 = ΔJ ustifiable by DALYs averted + ΔJ ustifiable by EOT = $\lambda_{\rm DALY}^{\rm WTP}$ \times $\Delta DALYs$ + ΔJ ustified by EOT

where

 Δ Justifiable by EOT := Differential costs in iterations where interventions lead to different elimination outcomes

³⁶ Apportioning the costs to one of these categories (averting disease vs elimination) will have to satisfy certain properties and ³⁷ principles.

³⁸ **A. Justifiable costs of disease control.** We denominate the justifiable costs of disease control are the product of DALYs averted ³⁹ and the willingness-to-pay:

$$
\lambda_{\rm DALY}^{\rm WTP} \times \Delta {\rm DALYs}
$$

⁴¹ We follow established conventions to calculate DALYs and evaluate the estimates in present-day terms (after applying [4](#page-6-0)2 discounting), as discussed in section $4(3-5)$ $4(3-5)$.

⁴³ It should be noted that all CEAs require a time-horizon, approximately the health planner's investment horizon. Mathemat-⁴⁴ ically, the application of a time-horizon means that all DALYs and costs are discounted at 3% per year for the duration of the ⁴⁵ horizon (twenty years in this paper) and 100% discounting thereafter.

⁴⁶ **B. Justifiable costs of elimination of transmission.** We designate the justifiable cost per additional percentage point in predicted ⁴⁷ to achieve EOT:

$$
100 \times \lambda_{\rm EOT}^{\rm WTP} \times \Delta \mathbb{I}_{\rm EOT}(\theta_i)
$$

⁴⁹ The justifiable cost of EOT must satisfy these properties:

• There must be a reference to whether an intervention leads to elimination. Because this formulation deals with each Monte Carlo iterate, the reference will be an indicator variable of the difference in the elimination outcome of each intervention (the outcome achieved when using the same parameter set to simulate the health and cost outcomes):

$$
\Delta \mathbb{I}_{\text{EOT}} = \mathbb{I}_{\text{EOT}}^{\text{strat A}} - \mathbb{I}_{\text{EOT}}^{\text{strat}}
$$

 \overline{B}

⁵⁰ • Corollary: if two strategies achieve elimination, there is no premium for elimination between those two strategies, and all ⁵¹ costs must be justified on the grounds of efficient control efforts (on a cost-per-DALY basis).

Marina Antillon, Ching-I Huang, Kat S. Rock, Fabrizio Tediosi 3 of [20](#page-19-0)

In the single iteration, the value in the first column is comparable to the Premium_{FOT} divided by 100, since the Premium_{FOT} is denominated per percentage point gain in chances of EOT.

Abbreviations: C: Costs DALYs: disability-adjusted life-years EOT: elimination of transmission I: indicator term for reaching EOT λ^{WTP}: monetary willingness-to-pay to avert an additional DALY of disease.

• The justifiable cost of EOT is not conditioned on $\lambda_{\text{DALYs}}^{\text{WTP}}$, unlike the premium of elimination (see section [C\)](#page-3-0).

 • It is possible that the comparator in some iterates achieves elimination while the candidate strategy does not. In this case, the justifiable cost is negative, lowering the NMB and favoring the comparator overall. It is important to focus on the expected NMB over all iterations, which considers the better decision on the balance of all uncertainties, rather than focusing on individual iterates.

⁵⁷ The linear additive scale avoids mathematical problems between strategies that have the same probability of elimination ⁵⁸ (such that ∆Costs*/*∆Pr. EOT would be undefined). The interpretation of the justifiable cost of elimination for each iterate of ⁵⁹ the model is in Table [S1.](#page-3-1)

C. Premium of elimination of transmission (Premium_{EOT}). The premium of elimination, although intimately related to the justifiable cost of elimination, is not precisely the same thing. If $\Delta C \leq \lambda_{\text{DALY}}^{\text{WTP}} \times \Delta \text{DALY}$ then the additional costs of a strategy are justified on the grounds of efficient control efforts, and the "premium for elimination" is therefore 0. For that reason, the premium of elimination is a metric conditioned on the $\lambda_{\text{DALY}}^{\text{WTP}}$. Therefore, the Premium_{EOT} if formulated as follows, conditioning on WTP_{DALY} :

 $\text{Premium}_{\text{EOT}}|\lambda_{\text{DALY}}^{\text{WTP}} = \max\{\Delta \text{C} - \lambda_{\text{DALY}}^{\text{WTP}} \times \Delta \text{DALYs}, 0\}$

Fig. S1. Model of strategies against gHAT in DRC including active screening (AS) by mobile teams, passive surveillance (PS) in fixed health facilities. Cases detected by either mode are treated. In two strategies ('Mean AS' and 'Mean AS & VC') the active screening coverage is equal to the mean number screened during 2014–2018. In two other strategies ('Max AS' and 'Max AS & VC'), the coverage is the maximum number screened during 2000–2018. In strategies 3 and 4 vector control (VC) is simulated assuming a 80% tsetse density reduction after one year. PS is in place under all strategies. Figure reproduced under the creative commons licence from Antillon *et al.* [\(8\)](#page-19-5).

⁶⁰ **3. Transmission model**

A. Disease model. We employed a previously published dynamic, deterministic transmission Susceptible-Exposed-Infected- Recovered-Suceptible (SEIRS) model. While the model is detailed elsewhere [\(6,](#page-19-6) [7\)](#page-19-7), briefly, we simulated gHAT illness and vector transmission in a compartmental model described by deterministic features, simulated using a set of ordinary differential equations. The stochastic nature of the observations was conferred by sampling from the infected prevalence to simulate those individuals who are diagnosed and report for treatment, either in a fixed health facility or to a mobile screening unit, and whether imperfect diagnostics correctly detect cases or identifies non-infected people as cases.

 A Markov Chain Monte Carlo (MCMC) approach was previously used to generate posterior parameter sets for which the model outputs match the longitudinal data for different regions of the Democratic Republic of Congo (DRC) during 2000–2016. In the present study we selected three example regions – Kwamouth (Region 1), Mosango (Region 2), and Yumbi (Region 3) – of the 168 originally fitted as examples for illustrating this new health economic framework.

⁷¹ **B. Strategies and intervention model.** The locations used in the current analysis are described in Table [S2.](#page-4-0) We chose these ⁷² health zones in order to highlight diverse results of our new framework.

Table S2. Descriptive summaries of three health zones.

N.B.: For Kwamouth, the extent of riverbank where vector control must be performed is informed by planned activities. For Mosango and Yumbi, assumptions regarding vector control are based on the experience in places of similar size.

 B.1. Medical Interventions. While the projections of strategies have been detailed in previously published manuscripts [\(8,](#page-19-5) [9\)](#page-19-8), we provide a brief sketch of the features of the simulation within the context of the current analysis. To determine the number of cases detected by screening as well as the time lived with disease for cases that were never detected, we simulated a diagnostic algorithm combined with the prevalence determined by the transmission model. Although diagnostic algorithms are elaborate π in practice, we simulated a simple algorithm that would capture the major features of the real process [\(10,](#page-19-9) [11\)](#page-19-10). Suspects in traditional active or passive surveillance activities are first screened by the Card Agglutination tests for Trypanosomiasis (CATT) or rapid diagnostic tests (RDTs). Serologically-positive suspects then have blood drawn for microscopy observation of the blood, and if trypanosoma are found, a patient undergoes a lumbar puncture to stage their disease (early infection is "stage 1" and late is "stage 2") and determine care. For those ineligible for oral fexinidazole treatment, staging of the disease is done via lumbar puncture and followed by either treatment with pentamidine (stage 1) or nifurtimox-eflornithine combination

 se treatment (NECT, stage 2) $(8, 12)$ $(8, 12)$ $(8, 12)$.

B.2. Vector control. To control the population of tsetse, special "Tiny Targets" have been developed that stand on riversides – $\frac{1}{85}$ typical tsetse habitat – and deliver deadly insecticide upon contact $(13-16)$ $(13-16)$. The advantage of this method of control of disease is that it breaks the chain of transmission, even when some cases cannot be reached for treatment. Activities entail placing

 Tiny Targets alongside the riverbanks twice per year for as many years as it takes to see a decline in the transmission of cases. The impact of these activities on tsetse density has been documented elsewhere [\(15,](#page-19-14) [16\)](#page-19-13) and its impact on disease transmission

has been evaluated in one modeling study for Chad [\(17\)](#page-19-15) and through analysis of case reporting in Guinea [\(18\)](#page-19-16).

 In our study, we calculate that vector control will have to be deployed along 437 km of riverbank in Kwamouth but only 210 km of riverbank in Mosango and Yumbi. The reason is that we assumed that smaller health zones like Mosango and Yumbi would need vector control activities closer to those in Yasa Bonga, a health zone of 2,606 km^2 [\(16\)](#page-19-13). Kwamouth, by contrast, s spans $14,589 \text{ km}^2$ and contains two hot spots of transmission and therefore requires a broader treatment of riverbanks [\(8\)](#page-19-5).

B.3. Interventions in the endgame. In simulating the end-game, we also assumed that additional confirmatory procedures such 95 as video microscopy (or lab-based tests) are being used to elevate the previous high specificity of screening algorithms (\approx 99.9%) to 100% in this context of diminishing prevalence [\(7\)](#page-19-7). We further simulate the impact of stopping active screening and vector control interventions (where applicable) based on observing three consecutive years of zero cases reporting (in either active screening or passive surveillance). Our algorithm would allow restarting active screening should further cases later arise through continuing passive detection. This cessation criterion is not only plausible in practice (it is unlikely that interventions would continue indefinitely) but also is important in capturing the impact of stopping transmission and therefore saving future intervention costs.

 C. Key outputs. The key outputs of the dynamic and diagnostic models include mortality in undetected cases, detected cases in stages 1 and 2, and DALYs before and after presenting to care for all interventions. The number of people actively screened, and number (if any) of vector deployments performed each year is recorded.

 D. Elimination of Transmission. Elimination of transmission (EOT) is assumed when the underlying transmission (not detected cases) falls below 1 new infection per year (this proxy threshold is necessary when using a deterministic model to approximate peri-elimination dynamics and has been used elsewhere $(9, 19)$ $(9, 19)$ $(9, 19)$. The metric of interest in this paper is regional EOT (where baseline activities must remain to prevent re-establishment) rather than eradication because we are not treating the issue of importation of cases [\(20\)](#page-19-18). This is also related to the World Health Organization's gHAT goal for 2030 which is global EOT to humans [\(21\)](#page-19-19).

4. Health Impact

 We measured health impact by combining the epidemiological outputs from the dynamic/screening model with a probability tree that simulates the branching process of treatment progression and disease outcomes.

 In accordance with the WHO interim guidelines on gHAT treatment [\(12\)](#page-19-11), we assumed that treatment would consist of 1800 mg of fexinidazole for four days and 1200 mg of fexinidazole for six days for most patients in stage 1 and 2 disease. We

 assumed that patients would be treated in equal parts on an inpatient and outpatient basis (as directly-observed therapy). Patients who were either under 6 years old or under 20 kg in weight, undergo a lumbar puncture to determine disease stage and are sorted accordingly into pentamidine or NECT inpatient treatment.

 We simulated the disease process separately for stage 1 and stage 2 disease, and a small proportion of stage 1 cases are assumed not cooperate with care or to undergo treatment failure, and are thus added to the number of cases that undergo stage 2 care.

 The disease and treatment probability tree model is deterministic, formalized mathematically through the product of conditional probabilities of the outcome at each stage of disease and treatment progression (Fig [S2\)](#page-7-0). The disease tree model for stage 1 includes: follow-up (for patients lost-to-follow-up), the presence of side effects, treatment success or failure, diagnosis (in the case of treatment failure), and progression to stage 2 treatment (if applicable). For stage 2, additional steps include death due to treatment and the process of rescue treatment (for patients who fail first-choice treatment for stage 2).

 Health burden is denominated in DALYs, but we report cases and deaths for the benefit of the reader (Table 3). The probability of EOT is denominated as a probability, and we treat it separately to DALYs averted.

 Although the WHO CHOICE program recommends a 10-year time-horizon, as we believe that a 20-year time-horizon would be the shortest time-period that ought to be considered in order to allow the economic rewards of elimination by 2030 to be reaped. In fact, eradication of smallpox has been examined using an infinite time horizon with discounting [\(22\)](#page-19-20).

A. Disability-adjusted life-years. For the purpose of denominating disease burden in a metric that is commonly used in health economics, and the cost-effectiveness literature specifically, we use the disability-adjusted life-year, the sum of the years of life lived with disability (illness) (YLD) and the years of life lost by fatal cases (YLL) [\(5,](#page-19-4) [23\)](#page-19-21):

$$
DALY_{iterationi}(\text{strategy } j) = \sum_{i} YLL_{i} + YLD_{i}
$$

 Although we do not here treat the QALY, our methods are directly applicable to QALYs gained if one were to substitute them for DALYs averted.

137 **B. Years of life lost (YLL).** The years of life lost are the years that the individual i would have been expected to live less the age that the individual died in. The life-table method of accounting would take into account the age-specific life-expectancy, but we leave it out here for simplicity.

$YLL_i^{\text{undiscounted}} := \text{life } \text{expectancy} - \text{age at } \text{death}_i$

 To calculate discounted values, we must calculate the discounted years of life lost in terms of the year in which the death occurs, and then adjust the years lost to present day terms (by discounting a second time):

$$
YLL_i^{\text{discounted}} := \frac{1}{(1+r)^{(\text{year of death}_i - \text{present year})}} \sum_{k=1}^{YLL_i^{\text{undiscounted}}} \frac{1}{(1+r)^k}
$$

 We assumed that the mean age of death from gHAT is 26.6 years, according to the limited existing data on the age of infected $_{143}$ patients (8) .

 C. Years lived with disability (YLD). The years lived with disability are calculated as follows. It is important to note that disability and duration are conditioned on the stage for gHAT.

 $YLD_i^{\text{undiscounted}} := \text{duration} \times \text{disability weight}$

 For diseases like gHAT, which have more than one stage of illness, YLD should be calculated while conditioning on the stage, by applying the duration and the severity of each stage, as done in [\(8\)](#page-19-5). If we apply discounting, we must calculate the discounted years of life lost due to disability in terms of the year in which the individual experiences the disability:

$$
YLD_i^{\text{discounted}} := \sum_{\text{illness years}_i} \frac{YLD_i^{\text{undiscounted}}}{(1+r)^{(\text{illness years}_i-\text{present year})}}
$$

 We apply a disability weight, which ranges between 0 for perfect health and 1 for disability equal to death, to YLD (but not to YLL) in order to measure the severity of the target disease (gHAT in this manuscript) relative to other diseases. Analysis of strategies against deadlier diseases would therefore be appear be cost-effective at lower willingness-to-pay values than milder diseases. These weights are calculated via studies that measure disability for a compendium of common illness symptoms (both acute and chronic). We use the disability weights provided by the Global Burden of Disease study [\(24\)](#page-19-22).

Marina Antillon, Ching-I Huang, Kat S. Rock, Fabrizio Tediosi 7 of [20](#page-19-0)

Fig. S2. Model of treatment for gHAT stages 1 and 2. Figure reproduced under the creative commons licence from Antillon *et al* [\(8\)](#page-19-5).

¹⁵⁴ **5. Costs**

 We performed our analysis using the health payer perspective, and therefore, only direct medical costs are included in our analysis. The cost function structure is identical to that described in [\(8\)](#page-19-5), and therefore we only briefly describe the main features here, but assumptions behind consumption vary slightly. The intermediate costs of strategies in each of the three regions are shown in tables [S4–](#page-8-0)[S12,](#page-12-0) as the strategies have different assumptions about consumption.

¹⁵⁹ Intervention costs are estimated as the product of unit costs and appropriate units as informed by the extant literature on ¹⁶⁰ interventions and our collaborators in DRC. Accelerating costs per case found towards the end-game is the results from a ¹⁶¹ decreasing number of cases.

¹⁶² Disease costs are linked to the probability tree model of treatment progression, and include diagnosis, confirmation, and ¹⁶³ staging, as well as the cost of the drug itself and the administration. Costs values are drawn from the literature. Where no cost ¹⁶⁴ data existed, WHO CHOICE costs were used. All costs are inflated to 2018 US\$ values.

¹⁶⁵ There are three first-line treatments available for gHAT treatment: Pentamidine, for stage 1 only; NECT, for stage 2 only;

¹⁶⁶ and fexinidazole, which can be administered for stages 1 and 2 with some exceptions delineated by the 2019 WHO interim

¹⁶⁷ guidelines on gHAT treatment [\(12\)](#page-19-11). The construction of the cost function for treatment is identical to that in [\(8\)](#page-19-5), but we ¹⁶⁸ reproduce here (with permission) the fundamental results of costs per person, and the proportion of individuals we believe will need each treatment:

Table S3. Treatments and costs

¹ Cost per unit includes the PNLTHA mark-up

² Cost per unit is exclusive of screening and confirmation but includes staging costs. Screening and confirmation are attributed to false positive patients as well, so it is calculated as part of active screening and passive surveillance.

³ According to our literature search, most stage 2 patients are severe or late-stage, so we assumed most of them would get NECT. This contributes <1% of the total costs of the whole strategy, so our conclusions are robust to these findings.

169

¹⁷⁰ As with the health impact, we compute costs using a 20-year time-horizon to allow time to consider the economic rewards of ¹⁷¹ elimination by 2030. However, any other choice of time horizon would be equally amenable to use in this new framework.

¹⁷² We omit dominated strategies – strategies that cost more but avert fewer DALYs – and weakly dominated strategies – ¹⁷³ strategies with high ICERs that avert fewer DALYs than strategies with lower ICERs. We do not show confidence intervals in

¹⁷⁴ ICERs as there are a variety of issues with the mathematical properties of such constructions [\(1\)](#page-19-1).

Table S4. Active screening: cost function

¹ Ideally, CATT tests would be used for active screening and RDT tests would be used for passive surveillance because of the high wastage of CATT tests in the context of passive surveillance settings.

Table S5. Components of active screening costs

Table S6. Cost breakdown for active screening activities per year

¹ Cost per unit includes the PNLTHA mark-up

Table S7. Passive surveillance: cost function

¹ Ideally, CATT tests would be used for active screening and RDT tests would be used for passive surveillance because of the high wastage of CATT tests in the context of passive surveillance settings.

Table S8. Components of passive surveillance costs

Table S9. Cost breakdown for passive surveillance activities per year

¹ Cost per unit includes the PNLTHA mark-up

Table S10. Vector Control: cost function

Table S11. Components of vector control costs

¹ Due to Kwamouth's large size and two transmission hotspots, VC is deployed in 432 km of river.

² While it is planned that 20 targets per km will be deployed in Kwamouth, we assumed the standard 40 targets per km in would need to be deployed in Mosango and Yumbi [\(25\)](#page-19-23).

Table S12. Cost breakdown for vector control activities

¹ Cost per unit includes the PNLTHA mark-up

¹⁷⁵ **6. Supplemental results**

Table S13. Intermediate outcomes, cost-effectiveness, and efficiency of elimination in Kwamouth (Region 1).

¹ Cases and deaths are undiscounted, whereas DALYs and costs are discounted at 3% per year.

² A dominated strategy is one that has a higher cost but averts fewer DALYs or has the same or lower probability of EOT than a less expensive strategy. A weakly dominated strategy has a higher ICER than the next more expensive strategy. See SI section [7.](#page-18-0)

³ We do not show prediction intervals for ICERs as there are a variety of issues with the mathematical properties of such constructions [\(1\)](#page-19-1).

⁴ For context on the values of $\lambda_{\text{DALY}}^{\text{WTP}}$ that we have chosen to display, see Table 2.

5 "Preferred" here refers to the strategy that would be considered optimal under traditional cost-effectiveness criteria (which does not account for EOT or reaching other global health goals).

Table S14. Intermediate outcomes, cost-effectiveness, and efficiency of elimination in Mosango (Region 2).

¹ Cases and deaths are undiscounted, whereas DALYs and costs are discounted at 3% per year.

² A dominated strategy is one that has a higher cost but averts fewer DALYs or has the same or lower probability of EOT than a less expensive strategy. A weakly dominated strategy has a higher ICER than the next more expensive strategy. See SI section [7.](#page-18-0)

³ We do not show prediction intervals for ICERs as there are a variety of issues with the mathematical properties of such constructions [\(1\)](#page-19-1).

⁴ For context on the values of $\lambda_{\text{DAIV}}^{\text{MTP}}$ that we have chosen to display, see Table 2.
⁵ "Preferred" here refers to the strategy that would be considered optimal under traditional cost-effectiveness criteria (w reaching other global health goals).

Table S15. Intermediate outcomes, cost-effectiveness, and efficiency of elimination in Yumbi (Region 3).

 1 Cases and deaths are undiscounted, whereas DALYs and costs are discounted at 3% per year.

² We do not show prediction intervals for ICERs as there are a variety of issues with the mathematical properties of such constructions [\(1\)](#page-19-1).

³ A dominated strategy is one that has a higher cost but averts fewer DALYs or has the same or lower probability of EOT than a less expensive strategy. A weakly dominated strategy has a higher ICER than the next more expensive strategy. See SI section [7.](#page-18-0)

⁴ For context on the values of $\lambda_{\text{DAIV}}^{\text{MTP}}$ that we have chosen to display, see Table 2.
⁵ "Preferred" here refers to the strategy that would be considered optimal under traditional cost-effectiveness criteria (w reaching other global health goals).

Fig. S3. Components of mean annual and cumulative costs, by strategy and location. Displayed costs are not discounted. Treatment costs, indicated in purple, are shown here although they are so small as to be hardly visible.

Fig. S4. Disability-adjusted life-years (DALYs) lost per strategy by location, 2020-2040. DALYs are not discounted. Estimates shown are means and their 95% predictive intervals (PI).

Fig. S5. Costs per strategy by location, 2020-2040. Costs are not discounted. Estimates shown are means and their 95% predictive intervals (PI).

¹⁷⁶ **7. Incremental cost-effectiveness ratios, dominance, and weak dominance**

¹⁷⁷ We show here a step-by-step calculation of incremental cost-effectiveness ratios (ICERs) in an effort to explain why a strategy is considered "weakly" dominated. Below is the calculation for Region 3 (Yumbi).

Strategy	Δ Cost	Δ DALYs	Preliminary ICER	Final ICER
Mean AS		0	Minimum	Minimum
			cost	cost
Max AS	62,000	81	765	765
Mean AS & VC	691.000	196	5,470	Weakly
				dominated
Max AS & VC	700,000	227	290	4.370

Table S16. Computing incremental cost-effectiveness ratios (ICERs) for Yumbi.

178

 Preliminary ICERs show the difference in costs and effects between a given strategy and the next best strategy. Due to diminishing returns, ICERs increase with more ambitious interventions, as it takes more money to avert fewer and fewer DALYs. ICERs displayed in red indicate a strategy that yields a worse value-for-money than the next best intervention; these ICERs are 'weakly dominated' and should not be adopted. Final ICERs are calculated after weakly dominated strategies are omitted. ICERs highlighted in yellow are those that differ from initial ICERs due to the removal of weakly dominated strategies.

¹⁸⁴ Even if one were to be willing to pay \$6,000 per DALY for another health service, then the Max AS & VC strategy should ¹⁸⁵ be chosen over the Mean AS & VC strategy to achieve elimination and to stay efficient.

¹⁸⁶ However, if the primary goal is to achieve elimination at the lowest cost, even if it is not efficient, then choose Mean AS & ¹⁸⁷ VC with the understanding that it is not the most efficient strategy in terms of cost-per-DALYs averted.

References

- 1. AA Stinnett, AD Paltiel, Estimating CE Ratios under Second-order Uncertainty. *Med. Decis. Mak*. **17**, 483–489 (1997).
- 2. AA Stinnett, J Mullahy, Net Health Benefits: A New Framework for the Analysis of Uncertainty in Cost-Effectiveness Analysis. *Med. Decis. Mak*. **18**, S68–S80 (1998).
- 3. JA Rushby, K Hanson, Calculating and presenting disability adjusted life years (DALYs) in cost-effectiveness analysis. *Heal. Policy Plan*. **16**, 326–331 (2001).
- 4. KP Claxton, et al., The Gates Reference Case for Economic Evaluation, (The Bill and Melinda Gates Foundation), Technical Report April (2014).
- 5. World Health Organization, *Making Choices in Health: WHO guide to cost-effectiveness analysis* eds. TTT Edejer, et al. (Geneva, Switzerland), (2003).
- 6. KS Rock, SJ Torr, C Lumbala, MJ Keeling, Predicting the Impact of Intervention Strategies for Sleeping Sickness in Two High-Endemicity Health Zones of the Democratic Republic of Congo. *PLoS Neglected Trop. Dis*. **11**, 1–17 (2017).
- 7. RE Crump, et al., Quantifying epidemiological drivers of gambiense human African Trypanosomiasis across the Democratic Republic of Congo. *medRxiv* (2020).
- 8. M Antillon, et al., Economic evaluation of gambiense human African trypanosomiasis elimination campaigns in five distinct transmission settings in the Democratic Republic of Congo. *medRxiv*, 2020.08.25.20181982 (2020).
- 9. CI Huang, et al., Shrinking the gHAT map : identifying target regions for enhanced control of gambiense human African trypanosomiasis in the Democratic Republic of Congo. *medRxiv* (2020).
- 10. F Checchi, F Chappuis, U Karunakara, G Priotto, D Chandramohan, Accuracy of five algorithms to diagnose gambiense human african trypanosomiasis. *PLoS Neglected Trop. Dis*. **5** (2011).
- 11. PR Bessell, et al., Cost-effectiveness of using a rapid diagnostic test to screen for human African trypanosomiasis in the Democratic Republic of the Congo. *PLOS ONE* **13**, e0204335 (2018).
- 12. WHO Department of Control of Neglected Tropical Diseases, WHO interim guidelines for the treatment of gambiense human African trypanosomiasis. (2019).
- 13. M Lehane, et al., Tsetse Control and the Elimination of Gambian Sleeping Sickness. *PLOS Neglected Trop. Dis*. **10**, e0004437 (2016).
- 14. NJ Mbewe, et al., Sticky small target: an effective sampling tool for tsetse fly Glossina fuscipes fuscipes Newstead 1910. *Parasites & Vectors* **11**, 268 (2018).
- 15. I Tirados, et al., Tsetse Control and Gambian Sleeping Sickness; Implications for Control Strategy. *PLOS Neglected Trop. Dis*. **9**, e0003822 (2015).
- 16. I Tirados, et al., Impact of Tiny Targets on Glossina fuscipes quanzensis, the primary vector of Human African Trypanosomiasis in the Democratic Republic of Congo. *bioRxiv*, 1–31 (2020).
- 17. MH Mahamat, et al., Adding tsetse control to medical activities contributes to decreasing transmission of sleeping sickness in the Mandoul focus (Chad). *PLoS Neglected Trop. Dis*. **11**, 1–19 (2017).
- 18. M Kagabadouno, et al., Ebola outbreak brings to light an unforeseen impact of tsetse control on sleeping sickness transmission in Guinea. *bioRxiv* (2018).
- 19. M Aliee, KS Rock, MJ Keeling, Estimating the time to extinction of infectious diseases in mean-field approaches. *medRxiv*, 2020.07.10.20150359 (2020).
- 20. WR Dowdle, The principles of disease elimination and eradication. *Bull. World Heal. Organ*. **76**, 22–25 (1998).
- 21. WHO Expert Committee on human African trypanosomiasis, Control and surveillance of human African trypanosomiasis: report of a WHO expert committee, Technical report (2013).
- 22. S Barrett, Economic considerations for the eradication endgame. *Philos. Transactions Royal Soc. B: Biol. Sci*. **368**, 20120149–20120149 (2013).
- 23. CJ Murray, Quantifying the burden of disease: The technical basis for disability-adjusted life years. *Bull. World Heal. Organ*. **72**, 429–445 (1994).
- 24. GBD 2017 DALYs and HALE Collaborators, Global, regional, and national disability-adjusted life-years (DALYs) for 359 diseases and injuries and healthy life expectancy (HALE) for 195 countries and territories, 1990-2017: A systematic analysis for the Global Burden of Disease Study 2017. *The Lancet* **392**, 1859–1922 (2018).
- 25. Liverpool School of Tropical Medicine, Use of Tiny Targets to control tsetse flies in Gambian HAT foci: standard operating procedures, Technical Report October (2016).